Company news
Dermata Therapeutics, Inc. news in 2025
Dermata Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.
Dermata Therapeutics Announces Closing of up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
December 29, 2025
Dermata Therapeutics Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
December 24, 2025
A New Realm of Skincare is Coming: Dermata Teases New OTC Brand Identity
December 4, 2025
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
November 14, 2025
Dermata Announces Acceptance of Patent Application for Next-Generation Acne Treatment by Australian Patent Office
October 2, 2025
Dermata Therapeutics Announces Presentation of Abstract at the European Academy of Dermatology and Venereology Congress 2025
September 17, 2025
Dermata Therapeutics to Present at the Life Sciences Virtual Investor Forum September 18th
September 16, 2025
Dermata Therapeutics Announces Strategic Pivot to Over-the-Counter Skin Care Treatments
September 10, 2025
Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
August 13, 2025
Dermata Receives Notice of Grant of Australian Patent for Topical Botulinum Toxin Treatment for Hyperhidrosis
July 8, 2025
Corporate Presentation 2025
June 10, 2025
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
May 14, 2025
Dermata’s XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks
April 15, 2025
Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
March 27, 2025
BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints
March 25, 2025
Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results
March 17, 2025
Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI™ Phase 3 STAR-1 Clinical Trial for Acne
March 4, 2025
Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis
February 25, 2025
Dermata to Present on BioPub on January 31, 2025
January 28, 2025
Dermata Therapeutics Announces Closing of $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules
January 22, 2025
Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules
January 21, 2025
Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R)
January 20, 2025